N-arylpiperazinyl derivatives of 2,3-dihydrobenzoxazin[1,4]-3-ones synthesis and normolipemic activity.
Four series of N-arylpiperazinyl derivatives of the 7-substituted 2,3-dihydrobenzoxazin[1,4]-3-one were synthesized and preliminarily tested for hypolipemic activity. Substitutions in position 2 were performed. Hypotriglyceridemic activity was shown to be present in a number of compounds.
Depreux
P
P
Laboratoire de Chimie Therapeutique, Faculte des Sciences Pharmaceutiques et Biologiques, Lille, France.
Moussavi
Z
Z
Lesieur
D
D
Sauzieres
J
J
D000818:Animals; D000924:Anticholesteremic Agents / Q000138:chemical synthesis / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D011345:Fenofibrate / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D010078:Oxazines / Q000138:chemical synthesis* / Q000494:pharmacology; D010879:Piperazines / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013055:Spectrophotometry, Infrared; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D010078:Oxazines; D010879:Piperazines; D014280:Triglycerides; D002784:Cholesterol; D011345:Fenofibrate